Use of medicines in children is often off-label or off-evidence because essential information is lacking. Over the last two decades, consistent efforts have been made to render the regulatory framework more amenable to the needs of the pediatric population. Methodological progress is also evident. However, the consistent effort must be sustained.
No takes yet. Share an insight, caveat, or question.
Shinya Ito (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: